MicroRNAs in Preeclampsia: Bridging Diagnosis and Treatment
Authors:
- Angeliki GeredeAGAngeliki Gerede
- Sofoklis StavrosSSSofoklis Stavros
- Maria DanavasiMDMaria Danavasi
- Anastasios PotirisAnastasios Potiris
- Efthalia MoustakliEMEfthalia Moustakli
- Nikolaos MachairiotisNMNikolaos Machairiotis
- Athanasios ZikopoulosAZAthanasios Zikopoulos
- Konstantinos NikolettosKNKonstantinos Nikolettos
- Peter DrakakisPDPeter Drakakis
- Nikolaos NikolettosNNNikolaos Nikolettos
- Makarios EleftheriadesMakarios Eleftheriades
- Ekaterini DomaliEDEkaterini Domali
Top Cited Papers
Open Access
- 15 March 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 2003
Abstract
Preeclampsia (PE) is a multifactorial hypertensive disorder that typically manifests after the twentieth week of pregnancy, significantly impacting perinatal mortality and neonatal morbidity. Its development is influenced by immunological components, systemic inflammation, and genetic factors, with placental malfunction playing a crucial role. While many aspects of its pathophysiology have been elucidated, its key mechanisms remain incompletely understood. MicroRNAs (miRNAs), small noncoding RNA molecules that regulate gene expression, have emerged as promising biomarkers and therapeutic targets in PE. Dysregulated miRNAs have been identified in pregnant PE patients, highlighting their role in disease onset. Placenta-specific miRNAs, such as miR-210 and miR-155, influence inflammation, endothelial function, and hypoxia responses, which are closely associated with PE development. These miRNAs play a crucial role in regulating trophoblast invasion, angiogenesis, and immune modulation, further linking their dysregulation to the pathophysiology of PE. This review aims to provide a comprehensive overview of the role of miRNAs in PE, focusing on their potential as diagnostic biomarkers and therapeutic targets. By integrating recent advancements in molecular research, we explore their implications in clinical practice, particularly in risk assessment, early detection, and novel treatment strategies.Keywords
This publication has 47 references indexed in Scilit:
- Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipidsInternational Journal of Pharmaceutics: X, 2024
- The emerging role of microRNA-based therapeutics in the treatment of preeclampsiaPlacenta, 2024
- Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?Journal of Reproductive Immunology, 2023
- Identification of novel microRNAs in the embryonic mouse brain using deep sequencingMolecular and Cellular Biochemistry, 2023
- Recent advances in understanding microRNA function and regulation in C. elegansSeminars in Cell & Developmental Biology, 2023
- Determinants of eclampsia in women with severe preeclampsia at Mpilo Central Hospital, Bulawayo, ZimbabwePregnancy Hypertension, 2021
- Pre-eclampsia: pathogenesis, novel diagnostics and therapiesNature Reviews Nephrology, 2019
- Association of raised blood lead levels in pregnant women with preeclampsia: A study at tertiary centreTaiwanese Journal of Obstetrics and Gynecology, 2019
- miR-210 Inhibits Trophoblast Invasion and Is a Serum Biomarker for PreeclampsiaThe American Journal of Pathology, 2013
- Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expressionOncogene, 2010